Abstract
Alzheimers disease (AD) is an incurable age-related neurodegenerative disorder characterized by profound memory dysfunction. This bellwether symptom suggests involvement of the hippocampus -- a brain region responsible for memory formation -- and coincidentally an area heavily burdened by hyperphosphorylated tau and neuritic plaques of amyloid beta (Aβ). Recent evidence suggests that pre-fibrillar soluble Aβ underlies an early, progressive loss of synapses that is a hallmark of AD. One of the downstream effects of soluble Aβ aggregates is the activation of the phosphatase calcineurin (CaN). This review details the evidence of CaN hyperactivity in ‘normal’ aging, models of AD, and actual disease pathogenesis; elaborates on how this could manifest as memory impairment, neuroinflammation, hyperphosphorylated tau, and neuronal death.
Keywords: Alzheimers, amyloid beta, calcineurin, calcium, pre-fibrillar soluble A, glycogen synthase kinase-3 beta (GSK-3 ), voltage-gated sodium (Na+), neurotransmitter, Ca2+ fluctuation
Current Neuropharmacology
Title: A Role for Calcineurin in Alzheimers Disease
Volume: 9 Issue: 4
Author(s): Lindsay C. Reese and Giulio Taglialatela
Affiliation:
Keywords: Alzheimers, amyloid beta, calcineurin, calcium, pre-fibrillar soluble A, glycogen synthase kinase-3 beta (GSK-3 ), voltage-gated sodium (Na+), neurotransmitter, Ca2+ fluctuation
Abstract: Alzheimers disease (AD) is an incurable age-related neurodegenerative disorder characterized by profound memory dysfunction. This bellwether symptom suggests involvement of the hippocampus -- a brain region responsible for memory formation -- and coincidentally an area heavily burdened by hyperphosphorylated tau and neuritic plaques of amyloid beta (Aβ). Recent evidence suggests that pre-fibrillar soluble Aβ underlies an early, progressive loss of synapses that is a hallmark of AD. One of the downstream effects of soluble Aβ aggregates is the activation of the phosphatase calcineurin (CaN). This review details the evidence of CaN hyperactivity in ‘normal’ aging, models of AD, and actual disease pathogenesis; elaborates on how this could manifest as memory impairment, neuroinflammation, hyperphosphorylated tau, and neuronal death.
Export Options
About this article
Cite this article as:
C. Reese Lindsay and Taglialatela Giulio, A Role for Calcineurin in Alzheimers Disease, Current Neuropharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157015911798376316
DOI https://dx.doi.org/10.2174/157015911798376316 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development
Mini-Reviews in Medicinal Chemistry Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Histamine H3 Receptor: A Potential Drug Target for the Treatment of Central Nervous System Disorders
Current Drug Targets - CNS & Neurological Disorders Alzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease
CNS & Neurological Disorders - Drug Targets Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy
Current Alzheimer Research Preventing the Spread of Alzheimer’s Disease Neuropathology: A Role for Calcilytics?
Current Pharmaceutical Biotechnology Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases
Current Medicinal Chemistry Local Flexibility Facilitates Oxidization of Buried Methionine Residues
Protein & Peptide Letters Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Emerging Biology of PDE10A
Current Pharmaceutical Design Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Nanoceria: Synthesis and Biomedical Applications
Current Nanoscience Editorial [Hot Topic: Drug Discovery for CNS Disorders: From Bench to Bedside (Guest Editor: Tiago Fleming Outeiro)]
CNS & Neurological Disorders - Drug Targets Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders
Current Molecular Pharmacology Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Role of Polyglycine Repeats in the Regulation of Glycogen Synthase Kinase Activity
Protein & Peptide Letters Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Symptomatic Improvement, Increased Life-Span and Sustained Cell Homing in Amyotrophic Lateral Sclerosis After Transplantation of Human Umbilical Cord Blood Cells Genetically Modified with Adeno-Viral Vectors Expressing a Neuro-Protective Factor and a Neural Cell Adhesion Molecule
Current Gene Therapy